Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) SEC filings page on Stock Titan provides access to the company’s public filings and related disclosures as they appear in the U.S. Securities and Exchange Commission’s EDGAR system. Mirum is a biopharmaceutical and rare disease company with approved therapies such as LIVMARLI, CHOLBAM and CTEXLI and a pipeline that includes volixibat, brelovitug and MRM-3379, as described in its press releases.
Through this page, users can review Mirum’s current and historical filings, including Form 8-K reports that describe material events. Recent 8-K filings have covered topics such as an Agreement and Plan of Merger and Reorganization to acquire Bluejay Therapeutics, associated private placement subscription agreements, and corporate updates on financial results. Other 8-K disclosures include receipt of a Paragraph IV Certification Notice Letter related to a generic version of LIVMARLI and press releases furnished as exhibits discussing quarterly results.
Stock Titan enhances these documents with AI-powered summaries designed to highlight the main points of lengthy filings. For example, AI summaries can help readers quickly understand key terms of merger agreements, private placement structures, or the implications of patent-related notices referenced in Mirum’s 8-Ks. Users can also monitor unregistered sales of equity securities and other capital markets activities described in the filings.
This page updates as new Mirum filings are posted to EDGAR, giving investors and researchers a structured way to follow regulatory disclosures alongside the company’s rare disease commercial and development programs. Forms such as 10-K, 10-Q and additional 8-Ks, when available, can be reviewed with AI-generated insights to assist in interpreting Mirum’s reporting.
Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe exercised performance restricted stock units into 8,658 shares of common stock, each unit representing one share. On March 16, 2026, she sold 4,732 common shares at 91.9779 per share to cover tax withholding obligations related to this vesting, and held 8,429 shares afterward. Footnotes state the performance restricted stock units vest in stages over March 15, 2025–2027.
Mirum Pharmaceuticals CEO Christopher Peetz reported a mix of stock exercises and a tax-related sale. On March 15, 2026, he exercised performance restricted stock units covering 75,000 shares of common stock at a conversion price of $0.00, increasing his direct holdings.
On March 16, 2026, Peetz executed an open-market sale of 40,985 shares of common stock at an average price of $91.9779 per share. A footnote states these shares were sold to cover tax withholding obligations tied to the vesting of the performance restricted stock units, indicating a mechanistic, tax-driven transaction rather than a discretionary sale. After these transactions, he directly held 194,309 shares, with an additional 187,500 shares held indirectly by The Peetz Family Trust.
Mirum Pharmaceuticals submitted a Form 144 notice to sell 7,287 shares of Common Stock, tied to Restricted Stock Units vesting under a registered plan. The filing lists the proposed disposition by an issuer-related broker on 03/15/2026.
The filing also discloses two recent sales by Eric Bjerkholt: 1,421 shares sold on 01/22/2026 for $132,615.15 and 1,053 shares sold on 01/26/2026 for $101,290.18. The notice records the broker as Morgan Stanley Smith Barney LLC.
Joanne Quan reports proposed sale of 7,287 shares of Mirum Pharmaceuticals common stock. The Form 144 lists 7,287 shares tied to restricted stock units vesting under a registered plan and names Morgan Stanley Smith Barney LLC as broker, dated 03/16/2026. The filing also discloses prior dispositions of 6,911 shares on 01/20/2026 for $623,853.21 and 1,822 shares on 01/22/2026 for $170,038.51.
Mirum Pharmaceuticals notice of proposed sale: the filing reports a proposed sale of 16,515 shares of Common Stock, with an aggregate amount shown as $1,529,949.60, dated 03/16/2026. The filing states the securities are Restricted Stock Units vesting under a registered plan on 03/15/2026.
The filing also lists prior open-market sales by Peter Radovich of 2,382, 3,143 and 2,631 shares on 01/22/2026, 01/26/2026 and 02/02/2026, respectively, with corresponding aggregate values shown.
Mirum Pharmaceuticals submitted a Form 144 notice reporting proposed sales of Common Stock tied to Restricted Stock Units vesting under a registered plan. The filing lists a broker Morgan Stanley Smith Barney LLC and shows recent dispositions by a holder, including multiple small share sales in January–February 2026.
Mirum Pharmaceuticals reported reported transactions of Common Stock under Form 144 by Christopher Peetz. The filing lists three dispositions: 7,098 shares on 01/22/2026, 6,831 shares on 01/26/2026, and 9,108 shares on 02/02/2026. The shares are described as Restricted Stock Units vesting under registered plan, issued as compensation for services.
Saira Ramasastry reported a proposed sale of Common Stock. The notice covers 2,000 shares to be sold on 03/16/2026 pursuant to a stock option exercise for cash, listed as "ISSUER" in the filing.
The filing also lists recent dispositions by the same holder: 2,000 shares on 02/13/2026 for $204,180.00, 2,000 shares on 01/15/2026 for $181,980.00, 5,000 shares on 12/22/2025 for $400,000.00, and 2,000 shares on 12/18/2025 for $139,460.00.
Mirum Pharmaceuticals president and COO Peter Radovich exercised stock options to acquire 5,912 shares of common stock at an exercise price of $15.87 per share. These options were fully vested. Following the transaction, he directly owns 26,567 shares of common stock and holds 54,088 stock options.
No shares were sold and no tax-withholding dispositions were reported, making this a straightforward exercise-and-hold transaction that increases his direct equity stake in the company.
Mirum Pharmaceuticals files a shelf registration to permit resale of up to 8,960,998 shares of its common stock. The prospectus covers resale by selling stockholders of 8,960,998 shares, which include shares issued in connection with the January 23, 2026 acquisition of Bluejay, shares held back as indemnity, private placement shares and shares issuable upon exercise of pre-funded warrants.
The company states it will not receive proceeds from these resales and agreed to bear registration expenses; selling stockholders will pay distribution-related fees and commissions. The offering is for resale by holders and is subject to lock-ups and exercise limitations described in the prospectus.